Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,313 Shares of Company Stock

by · The Markets Daily

Palvella Therapeutics, Inc. (NASDAQ:PVLA – Get Free Report) COO Kathleen Goin sold 4,313 shares of the company’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $124.58, for a total value of $537,313.54. Following the sale, the chief operating officer owned 2,165 shares of the company’s stock, valued at $269,715.70. This trade represents a 66.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathleen Goin also recently made the following trade(s):

  • On Wednesday, September 16th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $152.24, for a total value of $654,936.48.
  • On Wednesday, August 19th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $152.21, for a total value of $654,807.42.

Palvella Therapeutics Stock Performance

PVLA traded down $1.29 on Friday, hitting $125.10. The company had a trading volume of 161,792 shares, compared to its average volume of 259,770. The stock has a fifty day moving average price of $143.08 and a 200-day moving average price of $134.55. Palvella Therapeutics, Inc. has a 12-month low of $68.96 and a 12-month high of $161.38. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -25.90 and a beta of -0.27.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.35). Analysts forecast that Palvella Therapeutics, Inc. will post -6.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on PVLA shares. Canaccord Genuity Group set a $232.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. William Blair initiated coverage on shares of Palvella Therapeutics in a report on Friday, October 16th. They issued an “outperform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Friday, September 25th. Chardan Capital assumed coverage on Palvella Therapeutics in a research report on Monday, September 21st. They set a “buy” rating and a $240.00 price target on the stock. Finally, Raymond James Financial set a $226.00 price objective on Palvella Therapeutics in a report on Friday, October 16th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Palvella Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $209.79.

View Our Latest Analysis on PVLA

Institutional Investors Weigh In On Palvella Therapeutics

A number of large investors have recently modified their holdings of the business. Sterling Capital Management LLC increased its holdings in shares of Palvella Therapeutics by 907.7% during the third quarter. Sterling Capital Management LLC now owns 393 shares of the company’s stock valued at $54,000 after acquiring an additional 354 shares in the last quarter. Avior Wealth Management LLC purchased a new position in shares of Palvella Therapeutics in the 3rd quarter valued at approximately $212,000. Arizona State Retirement System raised its position in shares of Palvella Therapeutics by 30.9% in the 2nd quarter. Arizona State Retirement System now owns 2,765 shares of the company’s stock valued at $423,000 after purchasing an additional 652 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in Palvella Therapeutics in the 2nd quarter worth approximately $35,000. Finally, Penn Capital Management Company LLC acquired a new stake in Palvella Therapeutics in the 2nd quarter worth approximately $841,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

(Get Free Report)

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.

Featured Stories